Abstract:High-grade gliomas (HGGs) are primary brain tumors associated with significant morbidity and mortality, and despite advances in neuro-oncology, the prognosis remains poor. Cold atmospheric plasma, a novel experimental anti-cancer therapeutic tool, is a near-room temperature ionized gas generated at atmospheric pressure. It has many promising results in vitro and in vivo with a variety of cancers. CAP cytotoxicity appears to be selective to cancer cells without significant damage to surrounding healthy tissues. We aim to evaluate the efficacy of CAP in generating tumor-selective cytotoxicity against high-grade glioma. B16, U87, GL261, patient derived high grade glioma, human neural stem cells (LM-NSC008) and astrocytes (NHA hTERT) were treated with CAP. Proliferation and propidium iodide (PI)/annexin V flow cytometry assays were employed to quantify cytotoxicity, cell cycle phases and apoptosis. Cells were pre-treated with ferroptosis inhibitors Ferrostatin-1 and Deferoxamine (DFO) in rescue assays. Cerebral organoids were transplanted with fluorescent tumor cell lines and stained with cleaved caspase-3, ki67 and transferrin receptor. CAP induces dose dependent cell death in all glioma cell lines tested. CAP induces an accumulation of intracellular ROS, most prominent in glioma cells. CAP-mediated cell death involves apoptosis and ferroptosis. CAP selectively leads to apoptosis in tumor implanted organoids and leads to decreased proliferation in malignant and non-malignant cells. CAP leads to a shift into G0 phase of all treated cells, malignant and non-malignant. CAP treatment induces dose-dependent increases in ROS and apoptosis in HGG lines tested more significantly than in NHAs and hNSCs. CAP induces decreased proliferation and G 0 phase cell cycle arrest in all CAP-treated cells. CAP-mediated cytotoxicity was significantly mitigated with DFO pre-treatment in HGG cells, suggesting that ferroptosis plays a critical role in the mechanism of CAP treatment in HGG. CAP led to selective glioma cell death in tumor implanted cerebral organoids.

On the selective killing of cold atmospheric plasma cancer treatment: Status and beyond

Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor

A New Physically Triggered Cell Death via Transbarrier Contactless Cold Atmospheric Plasma Treatment of Cancer Cells

Metabolome Analysis of Selective Inactivation of Human Melanoma and Normal Cells by Cold Atmospheric Plasma

Cold Atmospheric Plasma Activates Selective Photothermal Therapy of Cancer

Principles of using Cold Atmospheric Plasma Stimulated Media for Cancer Treatment

Preclinical Cold Atmospheric Plasma Cancer Treatment

Recent advances in cold atmospheric plasma for tumor therapy

Unleashing the Power of Cold Atmospheric Plasma: Inducing Mitochondria Damage‐Mediated Mitotic Catastrophe

Cold Atmospheric Plasma Conveys Selectivity Against Hepatocellular Carcinoma Cells via Triggering EGFR(Tyr1068)-Mediated Autophagy

Cold-atmospheric plasma induces tumor cell death in preclinical in vivo and in vitro models of human cholangiocarcinoma

Cold atmospheric plasmas target breast cancer stemness via modulating AQP3-19Y mediated AQP3-5K and FOXO1 K48-ubiquitination

The cellular ROS-scavenging function, a key factor determining the specific vulnerability of cancer cells to cold atmospheric plasma in vitro

Reactive oxygen species from non-thermal gas plasma (CAP): implication for targeting cancer stem cells

Enhancing Innate and Adaptive Immune Systems by Cold Atmospheric Plasma (CAP) and Its Antitumor Immunity

On the Anti-Cancer Effect of Cold Atmospheric Plasma and the Possible Role of Catalase-Dependent Apoptotic Pathways

Cold Atmospheric Plasma: An Emerging Immunomodulatory Therapy

Surg-58. Cold Atmospheric Plasma (Cap) Causes Selective Tumor Cell Death Via Apoptosis And Ferroptosis In Malignant Glioma Cells

Cold Atmospheric Plasma: Possible Cure of Autoimmune Disorders and Cancer Via Attenuating Inflammation

Plasma Medicine and The Application in Tumor Therapy

The quest to quantify selective and synergistic effects of plasma for cancer treatment: Insights from mathematical modeling